Miikka Vikkula/LinkedIn
Dec 25, 2025, 13:41
Miikka Vikkula on a Treatment Advance: How Sirolimus Dosing Can Be Adapted for Vascular Malformations
Miikka Vikkula, Vice President at International Society for the Study of Vascular Anomalies (ISSVA), shared a post on LinkedIn:
“Congratulations Emmanuel on this online publication showing how sirolimus treatment can be adapted to patients’ needs. Most patients with slow-flow vascular malformations benefit to some extent, and many experience significant symptom reduction even with intermittent dosing. This is a big step forward in the multimodal management of vascular malformations”
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Feb 24, 2026, 14:31Augustina Isioma Ikusemoro: What Happens After You Donate Blood?
-
Feb 24, 2026, 14:27Eloïse Laouenan: Rising Risk of Pregnancy Related Venous Thromboembolism
-
Feb 24, 2026, 14:01A European Action Plan on Rare Diseases Is a Necessity, Not an Option – EPODIN
-
Feb 24, 2026, 13:59Riitta Lassila: How APAC Impacts the Interplay Between Complement and Coagulation
-
Feb 24, 2026, 13:29Win Ratio Analysis of Edoxaban vs Dalteparin in Cancer-Associated VTE – JTH
-
Feb 24, 2026, 13:28EAHAD Welcomes New Members to the Nurses Committee
-
Feb 24, 2026, 13:25AbQader Bedil: Donor Ferritin Testing and Iron Care
-
Feb 24, 2026, 12:53Tagreed Alkaltham։ Blood Is a Naturally Integrated and Adaptive Physiological System
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH